Essex Bio-Technology (HKG:1061) said the anti-VEGF ophthalmic injection bio-pharmaceutical product, HLX04-O, co-developed by two of its subsidiaries and Shanghai Henlius Biotech (HKG:2696), saw the last visit of the last patient (LPLV) for its phase 3 clinical study.
The study is a randomized, double-blinded, active-controlled, and global study conducted in patients with exudative age-related macular degeneration or wet-AMD, a Monday Hong Kong bourse filing said.
The drug is a new ophthalmic preparation product and is planned to be used for the treatment of wet-AMD in China.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。